HHS OIG: CMS Needs To Improve Oversight Of Part B Drug Prices

By Jessica Karins / January 17, 2023 at 1:18 PM
CMS needs to improve its oversight of Medicare Part B drugs’ average sales prices (ASPs) to ensure that providers are being correctly reimbursed and patients aren’t overcharged, the HHS Office of the Inspector General (HHS OIG) says. Ensuring the accuracy of ASPs is vital because CMS uses these prices to directly calculate payment amounts under Medicare Part B. Inaccurate ASPs can increase costs for Medicare and patients, or create drug access issues if providers are paid below cost, the HHS...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.